This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The strategies were monotherapy, parallel therapy, step-up therapy, step-down therapy, intensive step-up therapy, and monotherapy plus steroid. Patients were given biologics after the failure of two DMARDs.
The monotherapy DMARDs included methotrexate, sulfasalazine hydroxychloroquine, and cyclosporine. In parallel therapy, two or more DMARDs were given at the same time. In step-up therapy, patients began with DMARD monotherapy, and a second DMARD was added if an inadequate response was observed within the first six months. The step-down therapy started with parallel therapy, followed by a reduction in dose and withdrawal. In intensive stepup therapy, patients began with parallel therapy and the doses were rapidly increased if an inadequate response was observed within the first six months. In monotherapy plus steroid, glucocorticosteroids were routinely used alongside DMARD monotherapy; the other strategies used steroids as needed.
Location/setting
UK/primary and secondary care.
Methods

Analytical approach:
The analysis was based on a decision model that tracked the course of disease for hypothetical, individual patients, using their scores on the Health Assessment Questionnaire (HAQ). A lifetime horizon was considered. The analysis was performed as part of a UK National Institute for Health and Clinical Excellence (NICE) Clinical Guideline for Rheumatoid Arthritis. The authors stated that it was carried out from the perspective of the NHS.
Effectiveness data:
A systematic review was carried out to identify published sources for the clinical inputs. Only randomised controlled trials (RCTs) were included, if they were published in English and reported American College of Rheumatology (ACR) outcomes. Direct and indirect comparisons were carried out, using a mixed-treatment method (also known as a network meta-analysis). The treatment response rates were the key input to the model and were defined as the patients achieving ACR20 (20% improvement in certain criteria) or ACR50 after six months of treatment. Long-term data were from the
